– USA, CA – Kura Oncology, Inc. (Nasdaq: KURA) today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021, succeeding Robert Hoffman, who will be resigning from the board effective August 3, 2021.
Ms. Schafer will also succeed Mr. Hoffman as Audit Committee Chair at that time.
“I want to take this opportunity to express my sincere appreciation for Robert’s service and his many contributions throughout his six years on the Kura board,” commented CEO, Dr. Troy Wilson. “We are deeply grateful for his service as a board member and audit committee chair, and on behalf of everyone at Kura, we wish him well in his future endeavors.”
Ms. Schafer has more than 25 years of experience in healthcare investment banking, most recently as Vice-Chair of Equity Capital Markets at Wells Fargo Securities.
“Carol brings a wealth of experience as a trusted strategic and financial advisor to the leadership teams of growing biopharmaceutical companies,” said CEO, Dr. Troy Wilson. “We welcome her to the board and look forward to her contributions as we work to bring our oncology drug candidates to market, expand their use to larger patient populations and create value for patients and shareholders.”
About Carol Schafer
Carol Schafer currently serves as a Managing Partner at Hyphen Advisors. She previously served as Vice-Chair of Equity Capital Markets at Wells Fargo Securities, where she oversaw more than 200 transactions that raised nearly $90 billion in proceeds. Before that, Ms. Schafer served as VP, Finance and Business Development at Lexicon Pharmaceuticals.
Earlier, she held positions of increasing responsibility at J.P. Morgan, most recently as Managing Director of Equity Capital Markets. Ms. Schafer currently serves on the board of directors of Insmed, Idera Pharmaceuticals, and Repare Therapeutics, and she previously served on the board of Five Prime Therapeutics until its acquisition by Amgen in April 2021. She received a B.A. from Boston College and an MBA from New York University.
“Kura has a promising pipeline of oncology drug candidates, an impressive team, and the financial resources to create significant value,” said Carol Schafer. “I look forward to working with the leadership team and my fellow board members to help the company achieve its strategic objectives and realize this value.”
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations. Tipifarnib, a potent, selective, and orally bioavailable farnesyl transferase inhibitor has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma and is currently in a registration-directed study in patients with this devastating disease. Kura is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations.
For more information: https://kuraoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.